A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the ...

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines ...

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...